Statements (97)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
gptkb:Company |
| gptkbp:acquisition |
TIB Molbiol in 2019
Genentech in 2009 Spark Therapeutics in 2019 Chugai Pharmaceutical in 2002 Flatiron Health in 2018 Foundation Medicine in 2018 Roche Diagnostics in 1990 Roche Pharma in 1990 Ventana Medical Systems in 2008 |
| gptkbp:awards |
Innovation Award 2020
Top Employer Europe 2021 Sustainability Award 2020 recognized for innovation in healthcare Best Workplaces 2021 awarded for corporate social responsibility awarded for workplace culture Best Employer in Switzerland 2020 |
| gptkbp:capital |
approximately 200 billion CHF (2023)
approximately 200 billion CHF (2021) |
| gptkbp:ceo |
gptkb:Severin_Schwan
Severin Schwan since 2008 |
| gptkbp:clinical_diagnostics |
leader in clinical diagnostics market
|
| gptkbp:clinical_trial |
invests heavily in clinical research
conducts numerous clinical trials globally over 1,000 ongoing trials |
| gptkbp:collaborations |
collaborates with academic institutions
collaborates with healthcare providers collaborates with governments |
| gptkbp:community_engagement |
promotes health education initiatives
engages in community health initiatives supports local health programs |
| gptkbp:community_health |
contributes to global health initiatives
supports access to medicines programs partners with NGOs for health projects |
| gptkbp:divisions |
Pharmaceuticals
Diagnostics |
| gptkbp:employees |
approximately 100,000
around 100,000 (2020) |
| gptkbp:founded |
gptkb:1896
|
| gptkbp:founded_in |
gptkb:1896
|
| gptkbp:founder |
gptkb:Fritz_Hoffmann-La_Roche
|
| gptkbp:funding |
approximately 12 billion CHF (2022)
|
| gptkbp:global_presence |
operates in over 100 countries
|
| gptkbp:has_headquarters_in |
gptkb:Basel,_Switzerland
|
| gptkbp:headquarters |
gptkb:Basel,_Switzerland
|
| https://www.w3.org/2000/01/rdf-schema#label |
Roche Holding AG
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:instruction_set |
strong product pipeline in oncology
strong product pipeline in personalized medicine strong product pipeline in rare diseases |
| gptkbp:invention |
holds numerous patents in pharmaceuticals
over 20,000 patents filed holds numerous patents in diagnostics |
| gptkbp:investment |
invests in digital health technologies
invests in artificial intelligence in healthcare invests in data analytics for drug development |
| gptkbp:operates_in |
Pharmaceuticals
Diagnostics |
| gptkbp:partnership |
gptkb:Astra_Zeneca
gptkb:Gilead_Sciences gptkb:Abb_Vie gptkb:Illumina gptkb:Novartis |
| gptkbp:philanthropy |
gptkb:Roche_Foundation
gptkb:Roche_Diabetes_Care gptkb:Roche_Global_Health_Initiative Roche Community Program Roche Patient Assistance Program |
| gptkbp:products |
biopharmaceuticals
diagnostics |
| gptkbp:research_and_development |
approximately 12 billion CHF (2020)
|
| gptkbp:research_focus |
neurology
oncology central nervous system disorders infectious diseases immunology |
| gptkbp:revenue |
63.3 billion CHF (2022)
63.3 billion CHF (2020) 61.5 billion CHF (2020) |
| gptkbp:stock_exchange |
gptkb:SIX_Swiss_Exchange
|
| gptkbp:stock_symbol |
gptkb:ROG
|
| gptkbp:subsidiary |
gptkb:Genentech
|
| gptkbp:sustainability_initiatives |
gptkb:supply_chain_management
community engagement diversity and inclusion access to healthcare environmental responsibility focus on environmental responsibility focus on social responsibility focus on governance |
| gptkbp:uses_technology |
strong focus on biotechnology
|
| gptkbp:website |
www.roche.com
|
| gptkbp:bfsParent |
gptkb:Genentech
gptkb:Roche_Diagnostics |
| gptkbp:bfsLayer |
4
|